In the context of colitis, STAT1 is implicated in mediating the pro-inflammatory effects of GBP5 (44), and the therapeutic efficacy of Tofacitinib in treating ulcerative colitis is associated with the downregulation of STAT1 expression (45). This evidence concerns the gene STAT1 and ulcerative colitis.